Calliditas Therapeutics Clocked Preliminary Net TARPEYO Revenues of $31M–$33M in Q4, FY23 Preliminary Net TARPEYO Revenues of $100M–$102M, up 170% YoY, FY23 Preliminary Total revenues of $110M–$113M
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics AB reported preliminary Q4 net TARPEYO revenues of $31M-$33M and FY23 net revenues of $100M-$102M, marking a 170% increase YoY. Total FY23 revenues are estimated at $110M-$113M, driven by TARPEYO sales, milestone payments, and royalty income. The company also saw a record number of TARPEYO prescriptions in Q4.
January 08, 2024 | 7:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics reported strong preliminary revenue growth for Q4 and FY23, with TARPEYO revenues significantly increasing by 170% YoY and total revenues estimated to reach up to $113M.
The substantial year-over-year growth in TARPEYO revenues and the record number of prescriptions indicate strong product performance and market acceptance, which is likely to be viewed positively by investors. The preliminary nature of the report means final numbers could differ, but the strong growth figures are likely to boost investor confidence in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100